Q-omics provides the consensus-scored LCE1F profile across patient tissues and cancer cell-line models. LCE1F expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LCE1F is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, LCE1F RNA expression shows 7,938 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, HNSC, and ESCA as cancer lineages where LCE1F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE1F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE1F survival associations across molecular data types. LCE1F RNA expression shows survival associations in the most cancer types (14), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE1F RNA expression–survival associations across cancer types. High LCE1F expression shows unfavorable associations in BLCA, KIRC, KICH, BRCA and STAD, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LCE1F RNA expression.
This table summarizes LCE1F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LCE1F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE1F shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher LCE1F RNA expression in tumor versus normal tissue (log2 FC = +1.738, t-test p = .001).
This table shows molecular features associated with LCE1F in patient tissues and cancer cell lines. In patient samples, LCE1F shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE1F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
